NYSE International 100
8.163,42
PKT
-45,56
PKT
-0,55
%
Werbung
Analysen zu NYSE International 100-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.02.24 | Shell (ex Royal Dutch Shell) Neutral | UBS AG | |
| 01.02.24 | Sanofi Buy | UBS AG | |
| 01.02.24 | GSK Underweight | JP Morgan Chase & Co. | |
| 01.02.24 | SAP Add | Baader Bank | |
| 01.02.24 | GSK Buy | Deutsche Bank AG | |
| 01.02.24 | GSK Buy | Deutsche Bank AG | |
| 01.02.24 | Deutsche Bank Buy | UBS AG | |
| 01.02.24 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 01.02.24 | ING Group Buy | UBS AG | |
| 01.02.24 | Deutsche Bank Buy | Warburg Research | |
| 01.02.24 | Deutsche Bank Overweight | JP Morgan Chase & Co. | |
| 01.02.24 | Deutsche Bank Outperform | RBC Capital Markets | |
| 31.01.24 | Novartis Kaufen | DZ BANK | |
| 31.01.24 | Santander Halten | DZ BANK | |
| 31.01.24 | Santander Sector Perform | RBC Capital Markets | |
| 31.01.24 | Allianz Overweight | JP Morgan Chase & Co. | |
| 31.01.24 | GSK Underweight | JP Morgan Chase & Co. | |
| 31.01.24 | BBVA Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 31.01.24 | GSK Buy | UBS AG | |
| 31.01.24 | BBVA Buy | UBS AG | |
| 31.01.24 | Novartis Buy | UBS AG | |
| 31.01.24 | Santander Buy | UBS AG | |
| 31.01.24 | AstraZeneca Sell | UBS AG | |
| 31.01.24 | Diageo Overweight | Barclays Capital | |
| 31.01.24 | BBVA Overweight | Barclays Capital | |
| 31.01.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 31.01.24 | Diageo Sell | UBS AG | |
| 31.01.24 | Diageo Outperform | Bernstein Research | |
| 31.01.24 | Diageo Sell | Deutsche Bank AG | |
| 31.01.24 | Nokia Buy | Deutsche Bank AG | |
| 31.01.24 | Vodafone Group Buy | Deutsche Bank AG | |
| 31.01.24 | BBVA Buy | Deutsche Bank AG | |
| 31.01.24 | Diageo Neutral | JP Morgan Chase & Co. | |
| 31.01.24 | Santander Neutral | JP Morgan Chase & Co. | |
| 31.01.24 | Mercedes-Benz Group (ex Daimler) Outperform | RBC Capital Markets | |
| 31.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 31.01.24 | Diageo Hold | Jefferies & Company Inc. | |
| 31.01.24 | BBVA Overweight | JP Morgan Chase & Co. | |
| 31.01.24 | Sanofi Buy | UBS AG | |
| 30.01.24 | Novartis Buy | UBS AG |